优甲乐联合131碘治疗甲状腺乳头状癌术后的临床疗效分析

The Clinical analysis of 131I Combination With Euthyrox On Papillary Thyroid Carcinoma Afer Surgery Treatment

目的:探讨甲状腺乳头状癌(PTC)患者术后应用131I联合优甲乐治疗的效果。方法:选择行甲状腺癌手术并经病理证实为甲状腺乳头状癌的患者173例,根据术后治疗方式不同分为对照组和实验组,对照组79例,术后单纯给予优甲乐治疗,实验组94例,在优甲乐治疗的基础上联合131I治疗。比较两组患者术后3年内的复发、转移情况及生存情况。结果:对照组复发13例,复发率16.46%(13/79),实验组复发4例,复发率4.26%(4/94),两组复发情况比较差异有统计学意义(P<0.05)。对照组出现癌症转移率13.92%(11/79),实验转移率4.26%(4/94),两组转移情况比较差异有统计学意义(P<0.05)。对照组死亡6例,死亡率7.59%(6/79),实验死亡1例,死亡率1.06%(1/94),两组死亡情况比较差异有统计学意义(P<0.05)。结论:131I联合优甲乐对甲状腺乳头状癌患者术后治疗,能够减少复发和转移的发生,提高患者生存率和生活质量。

Objective To analysis the clinical efficacy of 131 I combination with euthyrox on papillary thyroid carcinoma which had surgery treatment. Methods 173 cases PTC patients were divided into control and experimental groups according to postoperative treatment. The control group which had 79 cases only took euthyrox treatment. The experimental group which had 94 cases took 131 I combination with euthyrox treatment. After 3 years, compared the two groups of patients on recurrence, metastasis and survival. Results The rate of recurrence, metastasis and survivalof control group were 16.46%,13.92% and 7.59%.But he rate of recurrence, metastasis and survivalof control group were 4.26% ,4.26% and 1.06%.They were all lower than control group. And there were significant difference between two groups （P〈0.05）. Conclusion The clinical efficacy of 131 I combination with euthyrox on papillary thyroid carcinoma which had surgery treatment is better. It could reduce the recurrence and metastases, improve survival and quality of life.